Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

TO THE EDITOR: Chemotherapy for light chain (AL) amyloidosis is based on combinations developed for multiple myeloma.[1][1] A better understanding of susceptibility of the AL underlying clone to specific types of treatments[2][2] and the ability to identify cytogenetic patterns with different

[1]  D. Dingli,et al.  Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains , 2018, Leukemia.

[2]  A. Foli,et al.  Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. , 2018, Blood.

[3]  W. Tsai,et al.  Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study , 2017 .

[4]  D. Dingli,et al.  Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. , 2017, Blood.

[5]  P. Milani,et al.  Attitudes about when and how to treat patients with AL amyloidosis: an international survey , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[6]  H. Goldschmidt,et al.  AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. , 2017, Blood.

[7]  D. Dingli,et al.  Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category , 2017, Leukemia.

[8]  L. Staudt,et al.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. , 2017, Cancer cell.

[9]  P. Cascio,et al.  The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. , 2017, Blood.

[10]  M. Dimopoulos,et al.  BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. , 2017, Blood.

[11]  M. Fisher,et al.  Calcineurin Orchestrates Lateral Transfer of Aspergillus fumigatus during Macrophage Cell Death. , 2016, American journal of respiratory and critical care medicine.

[12]  P. Hawkins,et al.  European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Hose,et al.  Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. , 2016, Blood.

[14]  G. Merlini,et al.  What is new in diagnosis and management of light chain amyloidosis? , 2016, Blood.

[15]  A. Foli,et al.  Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. , 2015, Blood.

[16]  Susan O'Brien,et al.  Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. , 2015, Blood.

[17]  H. Kohrt,et al.  Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK , 2015, Proceedings of the National Academy of Sciences.

[18]  S. Mostowy,et al.  Phagocytosis-dependent activation of a TLR9–BTK–calcineurin–NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus , 2015, EMBO molecular medicine.

[19]  A. Foli,et al.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.

[20]  R. Advani,et al.  Bruton’s tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib , 2014, Therapeutic advances in hematology.

[21]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Foli,et al.  Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. , 2011, Clinical lymphoma, myeloma & leukemia.

[23]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[24]  T. Therneau,et al.  Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Peng Wu,et al.  Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. , 2016, Drug discovery today.